Lithium has occupied a unique and often controversial space in the pharmacopeia for nearly a century. Long established as the "gold standard" for the treatment of bipolar disorder, the mineral is now being re-evaluated through the lens of modern neuroscience as a potential safeguard against the ravages of Alzheimer’s disease and age-related cognitive decline. According to physician-scientist David Fajgenbaum, M.D., an associate professor at the University of Pennsylvania and a leading advocate for drug repurposing, lithium represents one of the most promising, yet overlooked, tools in the burgeoning field of neuroprotection. Speaking on a recent episode of the mindbodygreen podcast, Fajgenbaum highlighted a growing body of evidence suggesting that this simple element may play a physiological role in maintaining brain health—a role that could fundamentally shift how the medical community approaches the prevention of dementia.

The resurgence of interest in lithium is not merely a clinical curiosity but is part of a broader movement to identify new uses for existing, FDA-approved medications. Fajgenbaum’s perspective is shaped by his own extraordinary medical journey; after surviving five near-fatal episodes of Castleman disease, a rare hyper-inflammatory condition, he successfully identified a generic organ transplant drug that has kept him in remission for over a decade. This experience led to the founding of Every Cure, a non-profit organization dedicated to using artificial intelligence and data integration to unlock the "hidden" potential of the approximately 3,000 drugs already on the market. Lithium, a generic and inexpensive mineral, stands as a primary example of a substance that lacks the traditional profit incentives required for large-scale pharmaceutical trials, despite mounting evidence of its efficacy in neurodegeneration.

The Scientific Case for Lithium in the Aging Brain

The hypothesis that lithium might protect against Alzheimer’s disease is supported by a multi-layered body of research encompassing epidemiological data, post-mortem human brain analysis, and animal models. For years, researchers observed a curious trend in public health data: regions with higher trace levels of lithium in the municipal drinking water tended to report lower rates of dementia and suicide. While these observational studies were initially met with skepticism, recent laboratory breakthroughs have provided a more granular understanding of why lithium may be essential for the aging prefrontal cortex.

A landmark series of studies, including research published in early 2025 and 2026, has clarified the biological relationship between lithium levels and cognitive impairment. In a study analyzing post-mortem brain tissue, researchers found that individuals who suffered from mild cognitive impairment (MCI) and Alzheimer’s disease exhibited significantly lower concentrations of lithium in their brains compared to age-matched controls with healthy cognitive function. Crucially, this deficiency appeared to be specific to lithium; levels of other essential metals and minerals did not show the same drastic variance. This suggests that lithium depletion may be an early, detectable biomarker or even a driver of the pathological changes associated with Alzheimer’s.

Further evidence has emerged from controlled animal studies. In mouse models designed to mimic the progression of Alzheimer’s, researchers found that a diet deficient in lithium accelerated the formation of amyloid-beta plaques and tau tangles—the two primary hallmarks of the disease. Conversely, the introduction of lithium, specifically in the form of lithium orotate, was shown to not only halt the progression of neuroinflammation but also to reverse memory deficits in aging mice. Unlike the high-dose lithium carbonate used in psychiatric care, these studies utilized much lower, "nutritional" doses, which appeared to be sufficient to restore the brain’s homeostatic balance without the risk of toxicity.

A Chronology of Lithium’s Medical Evolution

To understand the current excitement surrounding lithium, it is necessary to examine its long and winding history in medical science:

• The 19th Century: Lithium was initially used in the mid-1800s as a treatment for gout and "brain exhaustion," often found in the mineral springs of popular spas.
• 1949: Australian psychiatrist John Cade discovered that lithium carbonate had a profound stabilizing effect on patients with chronic mania, marking the birth of modern psychopharmacology.
• 1970: The U.S. Food and Drug Administration (FDA) officially approved lithium for the treatment of manic episodes in bipolar disorder.
• 2010s: Epidemiological studies in Denmark, Japan, and Texas began to correlate trace lithium in water supplies with improved neurological outcomes in the general population.
• 2020-2024: Research shifted toward the molecular level, identifying lithium’s ability to inhibit GSK-3 (glycogen synthase kinase-3), an enzyme directly involved in the production of Alzheimer’s-related plaques and tangles.
• 2025-2026: Recent AI-driven data mining by organizations like Every Cure identified lithium as a top candidate for repurposing in the fight against neurodegenerative diseases.

Biological Mechanisms: How Lithium Protects Neurons

The neuroprotective properties of lithium are believed to stem from its influence on several critical intracellular pathways. One of the primary mechanisms is the inhibition of GSK-3. In a healthy brain, GSK-3 regulates various cellular functions, but in the context of Alzheimer’s, it becomes overactive, leading to the hyperphosphorylation of tau proteins and the subsequent collapse of neuronal transport systems. By "dialing down" GSK-3 activity, lithium may effectively slow the rate of neuronal death.

Additionally, lithium has been shown to increase the expression of Brain-Derived Neurotrophic Factor (BDNF), a protein that acts like "fertilizer" for the brain, supporting the survival of existing neurons and encouraging the growth of new ones. Furthermore, lithium appears to enhance autophagy—the cellular "recycling" process that clears out damaged proteins and metabolic waste. By promoting the removal of misfolded amyloid and tau proteins, lithium helps maintain a cleaner, more efficient environment for synaptic transmission.

The Barriers to Repurposing: The "Valley of Death"

Despite the compelling data, lithium faces significant hurdles in reaching the clinical standard of care for Alzheimer’s prevention. The primary obstacle is structural rather than scientific. Because lithium is a naturally occurring element and its medicinal forms (like lithium carbonate) have been generic for decades, there is no patent protection to incentivize pharmaceutical companies to spend the hundreds of millions of dollars required for Phase III clinical trials.

This gap is often referred to by researchers as the "Valley of Death" in drug development. While a new, multi-thousand-dollar-a-month monoclonal antibody treatment might receive heavy investment, a low-cost mineral like lithium languishes in the academic sphere. Dr. Fajgenbaum argues that this is where AI and non-profit initiatives must step in. By aggregating existing health records and molecular data, researchers can build a "virtual trial" that provides enough evidence to influence clinical guidelines without the traditional profit-driven model.

Official Responses and Clinical Caution

The medical community remains cautiously optimistic but emphasizes that the public should not engage in self-supplementation. The Alzheimer’s Association and various geriatric societies have noted that while the lithium data is "intriguing," it is not yet sufficient to recommend lithium supplements for the general population.

One primary concern is lithium’s "narrow therapeutic index." In the high doses used for bipolar disorder, lithium can be toxic to the kidneys and thyroid, requiring regular blood monitoring. While the doses discussed for brain aging are significantly lower, the long-term effects of low-dose lithium orotate in healthy adults have not been fully mapped in large-scale human populations. Medical professionals stress that any intervention involving lithium must be conducted under the supervision of a physician who can monitor metabolic and renal function.

Broader Impact and the Future of Brain Health

The re-evaluation of lithium reflects a broader shift in how society views Alzheimer’s disease. For decades, the focus was on finding a "cure" for patients who already exhibited symptoms. However, as our understanding of the disease evolves, it is becoming clear that Alzheimer’s is a decades-long process that begins with subtle biological shifts in midlife.

If lithium is eventually validated as a neuroprotective agent, it could lead to a preventative paradigm where "micro-nutritional" levels of the mineral are monitored and maintained as part of routine health screenings, much like Vitamin D or cholesterol. This would be a transformative development for public health, particularly as the global population ages. By 2050, the number of people living with dementia is projected to triple, creating an economic and social burden that current healthcare systems are ill-equipped to handle.

Dr. Fajgenbaum’s work serves as a reminder that the solutions to our most pressing health crises may not always come from the discovery of new molecules, but from the better utilization of the ones we already have. "We have thousands of drugs that are already sitting on the shelves of our local pharmacies," Fajgenbaum noted. "We just need the will and the data to figure out which ones can save our lives."

As research continues into 2026 and beyond, lithium stands as a beacon of hope for the "drug repurposing" movement. Whether it becomes a standard preventative measure or remains a fascinating piece of the neuroscientific puzzle, its story underscores a fundamental truth in modern medicine: sometimes, the most powerful answers are the ones that have been hiding in plain sight for over a century. For now, the focus remains on foundational brain health—exercise, sleep, and metabolic management—while the scientific community works to bring the "lithium hypothesis" from the lab to the clinic.